ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the approval of a Phase III clinical trial for IMM01 (Timdarpacept) in China, a novel molecule targeting CD47 for the treatment of chronic myelomonocytic leukemia (CMML) in combination with azacitidine. The company holds global rights to IMM01, which has shown promise with a favorable safety profile and ability to activate macrophages without binding to human red blood cells. While the company has patents for IMM01 in several regions, it cautions that success in development or marketability cannot be guaranteed.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.